Labajo, Erbien G.
HRN: 23-60-66 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/04/2023
MUPIROCIN 2%, 15G (TUBE)
09/04/2023
09/10/2023
TOPICAL
2%
BID
Infiltrated IV Site
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes